TORONTO, ONTARIO–(Marketwire – Dec. 19, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Biophysics Ltd today announced that Arch scientists have inhibited biofilm formation on titanium using the Company’s proprietary peptide technology.
2011
Arch Biopartners Engages Intertek Cantox to Devise Drug Development Plan for Lead Cancer Compound
TORONTO, ONTARIO–(Marketwire – Nov. 7, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) today announced it has engaged Intertek Cantox (“Cantox”) to devise the drug development plan for the Company’s lead compound, GH501a.
Arch Biopartners Identify Lead Compound for Pancreatic Cancer and Non Small Cell Lung Cancer
TORONTO, ONTARIO–(Marketwire – Sept. 7, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) today announced it has identified a lead compound, named GH501a, for further development as potential treatment for non small cell lung cancer and pancreatic cancer.
Arch Biopartners Hires Investor Relations Firm
TORONTO, ONTARIO–(Marketwire – July 18, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) announced today it has retained the services of Renmark Financial Communications Inc. (Renmark”) to perform investor relations activities.
Arch Biopartners Announces Issuance of New U.S. Patent for Biofilm Inhibitor
TORONTO, ONTARIO–(Marketwire – July 14, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) today announced the U.S. Patent and Trademark Office has issued a method and composition patent for an invention preventing or inhibiting the growth of biofilm formation on biotic and abiotic surfaces.
Arch Biopartners, U of Calgary Extend Agreement
TORONTO, ONTARIO–(Marketwire – July 6, 2011) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTC:FOIFF) today announced that the University of Calgary has extended the overhead agreement with its subsidiary Arch Biotech Inc.
Arch Biopartners Enters Agreement to Develop Prototype Diagnostic Imaging Agents for Brain Tumor Stem Cells
TORONTO, ONTARIO–(Marketwire – June 27, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Cancer Therapeutics (“ACT”) today announced ACT has entered into an Agreement for Research Services (the “Agreement”) with the National Research Council of Canada (NRC).
Arch Biopartners Scientists Awarded Funding to Further Develop Brain Tumour Targeting Technology
TORONTO, ONTARIO–(Marketwire – June 23, 2011) – Arch Biopartners Inc. (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Cancer Therapeutics (“ACT”) today announced Arch scientists Dr. Donna Senger and Dr. Stephen Robbins have been awarded $561,251 of peer reviewed research funding to support ongoing work in the area of malignant glioma and the development of brain tumour cell targeting technology.
Arch Scientists to Present at ESF-LFUI Conference in Austria
TORONTO, ONTARIO–(Marketwire – May 24, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Biophysics Ltd today announced that Arch scientists Randall Irvin and Elisabeth Davis will be presenting new data at a conference titled “Charge Transfer in Biosystems” sponsored by the European Science Foundation (“ESF”) and University of Innsbruck (“LFUI”) held July 17-22, 2011 at the Universitätszentrum Obergurgl in Tirol, Austria.
Arch Scientists Create New Bio-Organic Metal That Is Harder, Resists Corrosion
TORONTO, ONTARIO–(Marketwire – May 10, 2011) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Biophysics Ltd today announced that Arch scientists have reported details of their new technology development at the University of Alberta in the field of biophysics.